Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data
Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects...
Saved in:
Published in | Clinical pharmacology and therapeutics Vol. 91; no. 2; p. 227 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.02.2012
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects. We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology. Tariquidar was equipotent in humans and rats in its effect of increasing (R)-[(11)C]verapamil brain uptake (expressed as whole-brain volume of distribution (V(T))), with very similar half-maximum-effect concentrations. Both in humans and in rats, brain V(T) approached plateau levels at plasma tariquidar concentrations >1,000 ng/ml. However, Pgp inhibition in humans led to only a 2.7-fold increase in brain V(T) relative to baseline scans (before administration of tariquidar) as compared with 11.0-fold in rats. The results of this translational study add to the accumulating evidence that there are marked species-dependent differences in Pgp expression and functionality at the BBB. |
---|---|
AbstractList | Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects. We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology. Tariquidar was equipotent in humans and rats in its effect of increasing (R)-[(11)C]verapamil brain uptake (expressed as whole-brain volume of distribution (V(T))), with very similar half-maximum-effect concentrations. Both in humans and in rats, brain V(T) approached plateau levels at plasma tariquidar concentrations >1,000 ng/ml. However, Pgp inhibition in humans led to only a 2.7-fold increase in brain V(T) relative to baseline scans (before administration of tariquidar) as compared with 11.0-fold in rats. The results of this translational study add to the accumulating evidence that there are marked species-dependent differences in Pgp expression and functionality at the BBB. |
Author | Bauer, M Jäger, W Stanek, J Wadsak, W Zeitlinger, M Mitterhauser, M Müller, M Langer, Oliver Kuntner, C Böhmdorfer, M Löscher, W Matzneller, P Koepp, M Karch, R Bankstahl, J P |
Author_xml | – sequence: 1 givenname: M surname: Bauer fullname: Bauer, M organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 2 givenname: M surname: Zeitlinger fullname: Zeitlinger, M – sequence: 3 givenname: R surname: Karch fullname: Karch, R – sequence: 4 givenname: P surname: Matzneller fullname: Matzneller, P – sequence: 5 givenname: J surname: Stanek fullname: Stanek, J – sequence: 6 givenname: W surname: Jäger fullname: Jäger, W – sequence: 7 givenname: M surname: Böhmdorfer fullname: Böhmdorfer, M – sequence: 8 givenname: W surname: Wadsak fullname: Wadsak, W – sequence: 9 givenname: M surname: Mitterhauser fullname: Mitterhauser, M – sequence: 10 givenname: J P surname: Bankstahl fullname: Bankstahl, J P – sequence: 11 givenname: W surname: Löscher fullname: Löscher, W – sequence: 12 givenname: M surname: Koepp fullname: Koepp, M – sequence: 13 givenname: C surname: Kuntner fullname: Kuntner, C – sequence: 14 givenname: M surname: Müller fullname: Müller, M – sequence: 15 givenname: Oliver surname: Langer fullname: Langer, Oliver |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22166851$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kEtLAzEUhYMo1laXbiVLXUzNTSaZGXdSfEFBEV2JlJvH2Mi8zKQWV_51A-rqXDh8h3vOlOx2fecIOQY2BybKc9MMcc4ZwJxDsUMOQAqeKSnkhEzH8Z0xlldluU8mnINSpYQD8v3wNmStsx6js9R30QU00fcd1S5unevo6eNZ9gKweP1M1oCtbyh2lkYM_mPjLQaKkca1o-tNiwlr-t5mOqBPN4bgXbigSE3fDokYU_DWxzUNCbIY8ZDs1diM7uhPZ-T5-uppcZst72_uFpfLzIi8KDJZo1Tpf6tAmQo11twKk1c6FSkAlagq6TTUlQNuSmQgZM6YqhmrgBkt-Iyc_OYOG53qrobgWwxfq_8l-A_LGGBa |
CitedBy_id | crossref_primary_10_1159_000343243 crossref_primary_10_3390_pharmaceutics12100966 crossref_primary_10_1002_jcph_722 crossref_primary_10_1124_dmd_114_058685 crossref_primary_10_1186_s10194_024_01894_0 crossref_primary_10_2174_1872312815666220222091032 crossref_primary_10_1016_j_ejphar_2012_09_013 crossref_primary_10_1016_j_jointm_2023_01_001 crossref_primary_10_1007_s00232_015_9804_y crossref_primary_10_1111_cts_13804 crossref_primary_10_1016_j_brainresbull_2022_09_017 crossref_primary_10_1038_aps_2015_64 crossref_primary_10_1038_jcbfm_2015_19 crossref_primary_10_1021_jacs_2c03944 crossref_primary_10_1021_cn3001729 crossref_primary_10_1124_dmd_112_049577 crossref_primary_10_2967_jnumed_112_111732 crossref_primary_10_1093_brain_aws147 crossref_primary_10_2967_jnumed_112_118232 crossref_primary_10_1007_s11307_023_01864_z crossref_primary_10_1038_clpt_2013_34 crossref_primary_10_1093_ijnp_pyu078 crossref_primary_10_1038_jcbfm_2012_112 crossref_primary_10_1002_cpt_73 crossref_primary_10_1146_annurev_pharmtox_010617_052438 crossref_primary_10_1186_2191_219X_2_58 crossref_primary_10_1177_0271678X211045444 crossref_primary_10_3389_fonc_2020_561936 crossref_primary_10_1016_j_xphs_2023_10_034 crossref_primary_10_1016_j_pharmthera_2018_04_006 crossref_primary_10_1021_acs_molpharmaceut_3c01036 crossref_primary_10_1038_s41573_020_0080_x crossref_primary_10_2174_1872312813666190311125652 crossref_primary_10_1021_mp5008103 crossref_primary_10_1016_j_clgc_2019_05_016 crossref_primary_10_1212_WNL_0000000000000858 crossref_primary_10_1016_j_ejps_2019_105122 crossref_primary_10_1016_j_therap_2020_02_018 crossref_primary_10_1002_cmdc_201500420 crossref_primary_10_1016_j_nucmedbio_2015_09_003 crossref_primary_10_1177_0271678X231202336 crossref_primary_10_1002_jlcr_2993 crossref_primary_10_1021_jm301297f crossref_primary_10_1517_17425255_2013_741589 crossref_primary_10_1073_pnas_1312159110 crossref_primary_10_1016_j_nbd_2014_04_001 crossref_primary_10_1007_s00204_021_03115_y crossref_primary_10_1007_s13318_024_00908_1 crossref_primary_10_1016_j_zemedi_2014_02_003 crossref_primary_10_1016_j_tiv_2017_07_015 crossref_primary_10_1002_cpt_362 crossref_primary_10_1007_s11307_015_0883_z crossref_primary_10_1080_20502877_2019_1564003 crossref_primary_10_1124_dmd_114_059873 crossref_primary_10_1002_cbic_201300770 crossref_primary_10_1186_s12987_020_00202_7 crossref_primary_10_1186_s12987_024_00562_4 crossref_primary_10_1007_s13318_018_0474_x crossref_primary_10_1016_j_seizure_2024_05_007 crossref_primary_10_1016_j_ddtec_2014_03_014 crossref_primary_10_2967_jnumed_114_146894 crossref_primary_10_1016_j_xphs_2017_03_024 crossref_primary_10_3389_fphar_2021_698966 crossref_primary_10_1002_prp2_151 crossref_primary_10_1038_clpt_2014_70 crossref_primary_10_1016_j_ejps_2023_106404 crossref_primary_10_1016_S1474_4422_13_70109_1 crossref_primary_10_1208_s12248_015_9752_6 crossref_primary_10_1016_j_bmc_2016_05_039 crossref_primary_10_1016_j_ddtec_2014_03_008 crossref_primary_10_1021_acs_molpharmaceut_5b00168 crossref_primary_10_1016_j_drup_2015_02_002 crossref_primary_10_1016_j_neuroscience_2014_07_030 crossref_primary_10_1080_17425247_2016_1227786 crossref_primary_10_1124_dmd_115_065946 crossref_primary_10_2967_jnumed_115_158055 crossref_primary_10_1111_bcp_13301 crossref_primary_10_1016_j_heliyon_2022_e09777 crossref_primary_10_1097_WCO_0000000000000072 crossref_primary_10_3389_fnins_2017_00396 crossref_primary_10_1097_RLI_0b013e3182a70043 crossref_primary_10_1007_s10928_024_09957_0 crossref_primary_10_1097_ALN_0000000000000391 crossref_primary_10_1177_0271678X20965500 crossref_primary_10_1002_smll_202003309 crossref_primary_10_1128_AAC_00486_13 crossref_primary_10_1021_mp300472y crossref_primary_10_1016_j_brainres_2014_08_060 crossref_primary_10_1007_s00508_015_0778_7 crossref_primary_10_1016_j_biomaterials_2018_10_023 crossref_primary_10_1016_j_nucmedbio_2013_05_005 crossref_primary_10_1016_j_ejca_2013_01_001 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1038/clpt.2011.217 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1532-6535 |
ExternalDocumentID | 22166851 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GrantInformation_xml | – fundername: Austrian Science Fund FWF grantid: F 3513 |
GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AEYWJ AFBPY AFFNX AFFPM AGHNM AGQPQ AGYGG AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG CGR COF CS3 CUY CVF DCZOG DPXWK DU5 EBS ECM EE. EIF EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NPM NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR X7M Y6R YFH YOC YXB ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c3477-5fa56000d616c9abaf2d3c49b21671a63995eb1f9e12c8a01354006f00910cb32 |
IngestDate | Sat May 31 02:07:31 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3477-5fa56000d616c9abaf2d3c49b21671a63995eb1f9e12c8a01354006f00910cb32 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3685270 |
PMID | 22166851 |
ParticipantIDs | pubmed_primary_22166851 |
PublicationCentury | 2000 |
PublicationDate | February 2012 |
PublicationDateYYYYMMDD | 2012-02-01 |
PublicationDate_xml | – month: 02 year: 2012 text: February 2012 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical pharmacology and therapeutics |
PublicationTitleAlternate | Clin Pharmacol Ther |
PublicationYear | 2012 |
SSID | ssj0004988 |
Score | 2.380036 |
Snippet | Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp)... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 227 |
SubjectTerms | Animals ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors Blood-Brain Barrier - diagnostic imaging Blood-Brain Barrier - drug effects Brain - diagnostic imaging Brain - metabolism Calcium Channel Blockers - pharmacology Carbon Radioisotopes Dose-Response Relationship, Drug Humans Positron-Emission Tomography - methods Positron-Emission Tomography - statistics & numerical data Quinolines - blood Quinolines - pharmacology Rats Species Specificity Verapamil - pharmacokinetics |
Title | Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22166851 |
Volume | 91 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9RAEF6u9sUX0dbfWubBFqVdzSbZvaRvWpWiKIdcoShSdvc2paBnPHJC--If5D_ZmezuJVd_oL6EsJsLYb-PuZlh5hvGHhSqUsKWgg_xv4Zj_KW50WgMk1w7rawRtg0U37xV-wf5q0N5OBj86FUtzRvz2J79sq_kf1DFNcSVumT_AdnFS3EB7xFfvCLCeP0rjEfHNW9bP8htJOGHWZj8HauvKD-AsT7flM-E2NuUz79RtxXlNHzlJAbKX-cnEz0LPY1hZJ-vZjc0PWLb6BkNtfNN0babWtgmcJE-26G7rdM7iL2WdaeKfRoLNWOvV5ec13NPmkUG6L3D17TJxqXl1zpMrerqhHVzRkU6_sFRP39BhSCLWhAXbW7KlfSqJdEo-xFegXxp38J6KYGfLL_Xebef6sbrsqZi6Tk8pfpzS4M0FUoVXuX2z7sXhLjj1gpbwZCEZqxSYii24JZFESRc8UueLH0HCU6H314IXlonZnyVXQnRBzz1VLrGBm66xrZGHqjTHRj3ENqBLRj1IFxn3_t8gx7fIPANHr57xD8g0z4ueAYIPHQ8A90A0gBankGPZxB4tgsaOpYBsQyQZUAsu84OXr4Y7-3zMMCD2ywfDrmsNDnUyUQJZUttdJVOMpuXBk9jKDQ5xxJ9hap0IrWFxmgE44dEVQk5sdZk6Q12afpl6m4xkFLqpDAuy22el1QzjaG-zZwpCoc-rrvNbvqDPaq9SstRPPI7v925yy53hLzHVis0C-4--piN2WjRPQcL6n0p |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pgp-mediated+interaction+between+%28R%29-%5B11C%5Dverapamil+and+tariquidar+at+the+human+blood-brain+barrier%3A+a+comparison+with+rat+data&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Bauer%2C+M&rft.au=Zeitlinger%2C+M&rft.au=Karch%2C+R&rft.au=Matzneller%2C+P&rft.date=2012-02-01&rft.eissn=1532-6535&rft.volume=91&rft.issue=2&rft.spage=227&rft_id=info:doi/10.1038%2Fclpt.2011.217&rft_id=info%3Apmid%2F22166851&rft_id=info%3Apmid%2F22166851&rft.externalDocID=22166851 |